RGH 790

Drug Profile

RGH 790

Alternative Names: RGH-790

Latest Information Update: 14 Apr 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Gedeon Richter
  • Class Antipsychotics
  • Mechanism of Action Dopamine D2 receptor agonists; Dopamine D3 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Psychotic disorders

Most Recent Events

  • 14 Apr 2016 Discontinued - Phase-I for Psychotic disorders (In volunteers) in Hungary (PO)
  • 07 Nov 2012 Discontinued - Phase-I for Psychotic disorders in United Kingdom (PO)
  • 17 Oct 2012 Pharmacokinetics & adverse events data from a phase I trial in healthy volunteers presented at the 25th Annual Congress of the European College of Neuropsychopharmacology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top